SCHEMBL2079003

SCHEMBL2079003

COc1ccc(C=CC=CC(=O)O)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
THRB P10828 1/20 0.47
ATM Q13315 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ABCG2 Q9UNQ0 2/20 0.46
MAOB P27338 3/20 0.46
TNFRSF1A P19438 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2079001 1.00 MAPT (0.50) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL27173982 0.89 THRB (0.56) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL12784443 0.88 MAPT (0.50) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL10661702 0.85 MAPT (0.69) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6782178 0.85 MAPT (0.69) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL2082907 0.82 MAPT (0.47) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL2082909 0.82 MAPT (0.47) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL15163802 0.81 JUN (0.68) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL2079090 0.80 MAPT (0.55) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL2081406 0.80 CYP1A2 (0.50) MAPTALDH1A1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897601-B2 Cannabinoid receptor modulators INTERVET, INC. (US) 2011-03-01 US disclosed
EP-1973877-A2 CANNIBINOID RECEPTOR MODULATORS SCHERING CORPORATION (US) 2008-10-01 EP disclosed
US-20070197628-A1 Cannabinoid receptor modulators INTERVET INTERNATIONAL B.V. (NL) 2007-08-23 US disclosed
WO-2007084450-A2 CANNIBINOID RECEPTOR MODULATORS SCHERING CORPORATION (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197628-A1 Cannabinoid receptor modulators CNR1, CNR2, GPR18 MAPT 1582/4885ALDH1A1 1999/4885MEN1 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.